Scarica l'app Stockscreener
0.3375
7.83%
0.0245
Dopo l'orario di chiusura:
.33
-0.0075
-2.22%
Nkgen Biotech Inc Borsa (NKGN) Ultime notizie
OC500 2024: Paul Y. Song - Orange County Business Journal
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal
NKGen Flat on Presentation of Alzheimer's Treatment - Baystreet.ca
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
NKGen Biotech Presents Phase 1/2a Troculeucel Data in - GlobeNewswire
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
NKGen Biotech avoids Nasdaq delisting with regained compliance - Investing.com India
Navigating NKGN Stock: NKGen Biotech Inc Journey - The InvestChronicle
Post-Trade Analysis: NKGen Biotech Inc (NKGN) Slides -6.54, Closing at 0.23 - The Dwinnex
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - The Manila Times
NKGen Biotech undergoes dilutive stock issuance By Investing.com - Investing.com Canada
NKGen Biotech undergoes dilutive stock issuance - Investing.com India
NKGN stock touches 52-week low at $0.35 amid market challenges - Investing.com Australia
NKGen Biotech Announces Poster Presentations at the 17th - GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Market Watch Highlights: NKGen Biotech Inc (NKGN) Ends on an Upturn Note at 0.40 - The Dwinnex
NKGen Biotech directors resign after a year of service By Investing.com - Investing.com Australia
NKGen Biotech appoints new directors to its board By Investing.com - Investing.com South Africa
NKGen Biotech appoints new directors to its board - Investing.com India
NKGen Biotech Welcomes New Directors and Assigns Committees - TipRanks
NKGen Biotech directors resign after a year of service - Investing.com India
NKGen Biotech Announces Leadership Shuffle on Anniversary - TipRanks
NKGen Biotech faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech faces potential Nasdaq delisting - Investing.com
Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal
Analysts agree that Kenvue's Neutrogena needs a face-lift (KVUE) - Seeking Alpha
Nkarta Inc (NKTX)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Top investors say Krystal Biotech Inc (KRYS) ticks everything they need - SETE News
Investor’s Delight: Krystal Biotech Inc (KRYS) Closes Weak at 184.17, Down -0.17 - The Dwinnex
Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 5.21 - The Dwinnex
Raymond James Upgrades Nkarta Inc (NKTX) to a Strong buy from an Outperform - Knox Daily
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble? - Insider Monkey
ASB Consultores LLC Trims Stock Holdings in PENN Entertainment, Inc. (NASDAQ:PENN) - Defense World
NKGen Biotech issues shares for debt conversion - Investing.com
What was NKGen Biotech Inc (NKGN)’s performance in the last session? - US Post News
NKGN stock touches 52-week low at $0.45 amid market challenges - Investing.com
NKGN’s Stock Market Adventure: -82.15% YTD Growth Amidst Volatility - The InvestChronicle
Market Momentum: NKGen Biotech Inc (NKGN) Registers a -34.09 Decrease, Closing at 0.49 - The Dwinnex
NKGen Biotech appeals Nasdaq delisting decision - Investing.com
NKGen Biotech faces Nasdaq delisting over market value - Investing.com India
A closer look at NKGN’s price-to-free cash flow ratio - US Post News
Selling Your Nano Nuclear Energy Inc. (NASDAQ: NNE) Stock? Here’s What You Need To Know - Stocks Register
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate - GlobeNewswire
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial - StockTitan
NKGen Biotech amends agreement, increases share consideration By Investing.com - Investing.com Australia
New Outlook On Intelligent Bio Solutions Inc - Stocks Register
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):